View an archived version of our recent webinar
Accelerated vaccines development and production: in-process NGS QC testing for risk mitigations
Appropriate safety testing is an important part of vaccine development and production. As the impact of COVID-19 continues to be felt across the world, the biopharmaceutical industry more than ever needs fast and innovative solutions to accelerate the development and production of vaccines.
Next-generation sequencing (NGS) is a performant, validated, and secure method that brings significant advantages in terms of turnaround time, safety, and cost-effectiveness to the vaccine production process.
Watch this webinar replay where PathoQuest NGS expert, Magali Roche, Ph.D., reviews:
You can view a replay of this free webinar by clicking on the button above.